



IFW

File No.: 6013-149US MG/pd

Québec, Canada

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Philippe A. Tessier et al.  
Serial No.: 10/517,319  
Filing Date: July 15, 2005  
Art Unit: 1653  
Title: CHEMOTATIC FACTOR INHIBITOR FOR MODULATING  
INFLAMMATORY REACTIONS

-----

FIRST INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97

NO FEE

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on a PTO/SB/08A/B form is a listing of the documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56.

The submission of any document which is not a statutory bar is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

Statement of Relevancy

The listed document is being submitted either in compliance with 37 C.F.R. §1.97(b), within three (3) months of the filing date of a national application or of the date of entry of the national stage in an international application, or before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under §1.114; or pursuant to 37 C.F.R. §1.97(e)(1), within three (3) months from the date of an office action or of a search report issued in a foreign counterpart application citing each of the documents contained in the present statement; or pursuant to 37 C.F.R. §1.97(e)(2), within three (3) months from the first knowledge of each submitted document by any individual designated in C.F.R. §1.56(c), when each such document was not cited in a communication from a foreign patent office in a counterpart foreign application.

In the case of submission under 37 C.F.R. §1.97(e)(1) and (2), the undersigned Attorney/Agent of Record hereby certifies that the enclosed list of references is hereby submitted within three months (1) from the issuance of the foreign action or search report, or (2) from said first knowledge, respectively.

The Examiner is kindly requested to consider these references during the examination of the above-identified application, making the references of record, and to return an initialed copy of the PTO/SB/08A/B Form to the below-signed agent.

Respectfully,

April 26, 2006

Date

Marie-Hélène Rochon

Agent of the Applicant

Marie-Hélène Rochon, Reg. No. 57,566

OGILVY RENAULT LLP

Customer Number: 020988

A circular stamp from the Intellectual Property Office (IPO). The text "O I P E" is at the top, "I A P 3" is at the top right, "APR 28 2006" is in the center, and "PATENT &amp; TRADE MARK OFFICE" is at the bottom.

Sheet	1	of	2	Attorney Docket Number	6013-149US MG/pd
-------	---	----	---	------------------------	------------------

[illegible][illegible]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449A and B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/517,319
		Filing Date	07/15/2005
		First Named Inventor	Philippe Tessier
		Art Unit	1653
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	6013-149US MG/pd	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		DUNN C J ET AL: "Increased expression of neutrophil MRP8 and MRP14 is associated with vascular adhesion molecule activation and differential leukocyte infiltration in delayed-type hypersensitivity suggesting a proinflammatory role for S100 calcium-binding proteins" Biosis, XP002242712 abstract	
		YEN TINA ET AL: "Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli", Blood, W.B. Saunders, Philadelphia, VA, US, vol. 90, no. 12, 15 December 1997, pages 4812-4821	
		LAGASSE E ET AL: "Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage" Blood, W.B. Saunders, Philadelphia, VA, US, vol. 79, 1992, pages 1907-1915	
		LACKMANN M.: "Identification of a chemotactic domain of the pro-inflammatory S100 Protein CP-10", Journal of immunology, The Williams and Wilkins Co. Baltimore, US, vol. 150, no 7, April 1, 1993, pages 2981-2991	
		DEVERY JANNINE M ET AL: "Acute inflammatory activity of the S100 protein CP-10: Activation of neutrophils in vivo and in vitro." Journal of immunology, vol. 152, no. 4, 1994, pages 1888-1897	
		RYCKMAN CARLE ET AL: "Proinflammatory activities of S100: Proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion." Journal of immunology, vol. 170, no. 6, 15 March 2003, pages 3233-3242	
		ROULEAU PASCAL ET AL: "The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis.", Clinical immunology (Orlando), vol. 107, no.1, 20 April 2003, pages 46-54	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.